<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01574898</url>
  </required_header>
  <id_info>
    <org_study_id>V00474 PC 1 01</org_study_id>
    <secondary_id>2012-000419-94</secondary_id>
    <nct_id>NCT01574898</nct_id>
  </id_info>
  <brief_title>Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations</brief_title>
  <official_title>Pilot Pharmacokinetic Study of Three New Nicotine Lozenge Formulations (V0474) Versus Two Reference Formulations (V0018 B mg and Niquitin® Fresh Mint, 4mg) After Single Oral Administration in Healthy Male Smokers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetic profile of nicotine following a
      single oral administration of three new nicotine lozenge formulations (V0474) in comparison
      with two reference products. The clinical and biological safety of V0474 and the lozenge
      acceptability will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of nicotine following a single oral nicotine lozenge administration in healthy smokers</measure>
    <time_frame>12 time points up to 6h after oral administration</time_frame>
    <description>Pharmacokinetic profile of nicotine following a single oral nicotine lozenge administration in healthy smokers by measuring Maximum Plasma Concentration (Cmax), Time of Maximum Concentration (Tmax) , Area under the nicotine plasma concentration curve (AUC0-t), for each test and reference formulations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical safety (reported adverse events)</measure>
    <time_frame>Screening up to Day 5</time_frame>
    <description>Safety by evaluating the number of subjects with emergent adverse events and changes from baseline to end of study in vital signs, Electrocardiogram (ECG) and clinical laboratory parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability questionnaire</measure>
    <time_frame>Up to complete lozenge dissolution, about 30 minutes (4 times)</time_frame>
    <description>Quantitative and qualitative descriptive analysis of the scores reported by treatment and assessment time</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Healthy Smokers</condition>
  <arm_group>
    <arm_group_label>Niquitin® Fresh Mint 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>V0118 - B mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>V0474 - C mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>V0474 - B mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>V0474 - A mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0474 - A mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>V0474 - A mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0474 - B mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>V0474 - B mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0474 - C mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>V0474 - C mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0018 - B mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>V0118 - B mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niquitin® Fresh Mint 4 mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>Niquitin® Fresh Mint 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject aged 18 to 45 years (inclusive)

          -  Current smoker of &lt; or = 10 cigarettes/day

          -  Fagerström score &lt; or = 5

          -  Absence of any clinically significant abnormal finding at physical, ECG, biological
             examinations in the Investigator's opinion

        Exclusion Criteria:

          -  Presence of any significant medical finding or significant history (in particular any
             cardio-vascular disease, severe renal or hepatic insufficiency, current gastric or
             duodenal ulcer or oesophagitis) that may impact the safety, the interpretation of the
             results and/or the participation of the subject in the study according to the opinion
             of the investigator

          -  Current or recurrent buccal lesions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gieres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Nicotine</keyword>
  <keyword>Tobacco Use Disorder</keyword>
  <keyword>Central Nervous System Agents</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

